Difference between revisions of "Dinaciclib (SCH-727965)"
Jump to navigation
Jump to search
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
|||
Line 5: | Line 5: | ||
===[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]]=== | ===[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]]=== | ||
− | # Flynn J, Jones J, Johnson AJ, Andritsos L, Maddocks K, Jaglowski S, Hessler J, Grever MR, Im E, Zhou H, Zhu Y, Zhang D, Small K, Bannerji R, Byrd JC. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2015 Feb 24. [Epub ahead of print] [http://www.nature.com/leu/journal/v29/n7/full/leu201531a.html link to original article] [ | + | # Flynn J, Jones J, Johnson AJ, Andritsos L, Maddocks K, Jaglowski S, Hessler J, Grever MR, Im E, Zhou H, Zhu Y, Zhang D, Small K, Bannerji R, Byrd JC. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2015 Feb 24. [Epub ahead of print] [http://www.nature.com/leu/journal/v29/n7/full/leu201531a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25708835 PubMed] |
===[[Multiple myeloma]]=== | ===[[Multiple myeloma]]=== | ||
− | # Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single agent activity in patients with relapsed multiple myeloma. Blood. 2014 Nov 13. [Epub ahead of print] [http://www.bloodjournal.org/content/125/3/443 link to original article] [ | + | # Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single agent activity in patients with relapsed multiple myeloma. Blood. 2014 Nov 13. [Epub ahead of print] [http://www.bloodjournal.org/content/125/3/443 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25395429 PubMed] |
[[Category:Drug index]] | [[Category:Drug index]] |
Revision as of 02:49, 2 December 2016
Mechanism of action
A cyclin dependent kinase inhibitor that selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, and CDK9.
Preliminary data
Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Flynn J, Jones J, Johnson AJ, Andritsos L, Maddocks K, Jaglowski S, Hessler J, Grever MR, Im E, Zhou H, Zhu Y, Zhang D, Small K, Bannerji R, Byrd JC. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2015 Feb 24. [Epub ahead of print] link to original article PubMed
Multiple myeloma
- Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single agent activity in patients with relapsed multiple myeloma. Blood. 2014 Nov 13. [Epub ahead of print] link to original article PubMed